We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

56 hedge funds and large institutions have $8.12M invested in VistaGen Therapeutics in 2026 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,184% more call options, than puts

Call options by funds: $321K | Put options by funds: $25K

56% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 9

14% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 14

2.36% more ownership

Funds ownership: 34.82% → 37.18% (+2.4%)

2% more funds holding

Funds holding: 55 → 56 (+1)

8% less capital invested

Capital invested by funds: $8.84M → $8.12M (-$712K)

Holders
56
Holders Change
+1
Holders Change %
+1.82%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
14
Reduced
9
Closed
14
Calls
$321K
Puts
$25K
Net Calls
+$296K
Net Calls Change
+$164K

Top Buyers

1
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$358K
2
Two Sigma Investments
Two Sigma Investments
New York
+$167K
3
Millennium Management
Millennium Management
New York
+$142K
4
VA
Verdad Advisers
Massachusetts
+$112K
5
XT
XTX Topco
Cayman Islands
+$92.9K

Top Sellers

1
Jane Street
Jane Street
New York
-$155K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$117K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$101K
4
OAC
OMERS Administration Corp
Ontario, Canada
-$68.4K
5
Group One Trading
Group One Trading
Illinois
-$52.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$1.75M – – –
TCM
2
TCG Crossover Management
California
$1.53M – – –
VCM
3
Vanguard Capital Management
Pennsylvania
$900K +$956K +1,574,200 New
ACM
4
ADAR1 Capital Management
Texas
$429K +$77.5K +127,566 +20%
Acadian Asset Management
5
Acadian Asset Management
Massachusetts
$336K +$358K +589,663 New
IC
6
Ikarian Capital
Texas
$297K – – –
Two Sigma Investments
7
Two Sigma Investments
New York
$268K +$167K +274,049 +140%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$259K +$61.1K +100,555 +28%
BlackRock
9
BlackRock
New York
$256K +$15.6K +25,748 +6%
Millennium Management
10
Millennium Management
New York
$246K +$142K +233,359 +118%
LM
11
Luminus Management
Texas
$226K +$28K +46,053 +13%
Renaissance Technologies
12
Renaissance Technologies
New York
$166K +$79.3K +130,509 +81%
AI
13
AdvisorShares Investments
Maryland
$158K +$16.4K +26,922 +11%
Jane Street
14
Jane Street
New York
$156K -$155K -254,316 -48%
VFT
15
Vanguard Fiduciary Trust
Pennsylvania
$125K +$132K +217,700 New
VA
16
Verdad Advisers
Massachusetts
$106K +$112K +184,938 New
XT
17
XTX Topco
Cayman Islands
$87.4K +$92.9K +152,849 New
SC
18
Shay Capital
New York
$82.6K +$87.8K +144,452 New
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$81.5K -$117K -192,179 -57%
BFM
20
Boothbay Fund Management
New York
$76.9K – – –
State Street
21
State Street
Massachusetts
$69.2K – – –
Tudor Investment Corp
22
Tudor Investment Corp
Connecticut
$60.7K +$18.2K +30,000 +39%
DP
23
Diadema Partners
New Jersey
$60.3K +$3.3K +5,428 +5%
SC
24
Stempoint Capital
New York
$58.2K – – –
Simplex Trading
25
Simplex Trading
Illinois
$51.3K +$54.5K +89,649 New
1
2 3

VTGN Hedge Fund Activity: Q1 2026 in Review

56 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2026, worth a combined $8.12M — down 8.1% from $8.84M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new VTGN positions and 14 closed out — a net gain of 2 holders — while 14 added to existing stakes and 9 trimmed.

The largest buyer was Acadian Asset Management, opening a new position worth an estimated $358K. The largest seller was Jane Street, cutting an estimated $155K.

  • 56 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2026, up from 55 in Q4 2025.
  • Funds reported $8.12M of VistaGen Therapeutics stock for Q1 2026, down 8.1% quarter-over-quarter.
  • 16 funds opened new VistaGen Therapeutics positions in Q1 2026 and 14 closed out, a net change of +2 holders.
  • The largest VistaGen Therapeutics buyer in Q1 2026 was Acadian Asset Management, an estimated $358K added.
  • The largest VistaGen Therapeutics seller in Q1 2026 was Jane Street, an estimated $155K sold.

Based on aggregated 13F filings for Q1 2026.